Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has 5 years of Non-Current Deffered Revenue data on file, last reported at $253.4 million in Q1 2025.

• Quarterly Non-Current Deffered Revenue rose 10.92% year-over-year to $253.4 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $253.4 million (up 10.92% YoY) and the FY2024 annual result came in at $244.6 million, up 43.13% from the prior year.
• Non-Current Deffered Revenue grew to $253.4 million in Q1 2025, from $244.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $253.4 million in Q1 2025 to a low of $47.0 million in Q4 2021.
• A 5-year average of $151.2 million and a median of $138.3 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue soared 168.44% — and 2025, when it grew 10.92%.
• Tracing AUTL's Non-Current Deffered Revenue over 5 years: stood at $47.0 million in 2021, then surged by 167.78% to $125.9 million in 2022, then soared by 35.74% to $170.9 million in 2023, then surged by 43.13% to $244.6 million in 2024, then gained by 3.61% to $253.4 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $253.4 million (Q1 2025), $244.6 million (Q4 2024), and $248.9 million (Q3 2024), per Business Quant data.